Abstract
BackgroundPenicillium species are important producers of bioactive secondary metabolites. However, the immense diversity of the fungal kingdom is only scarcely represented in industrial bioprocesses and the upscaling of compound production remains a costly and labor intensive challenge. In order to facilitate the development of novel secondary metabolite producing processes, two routes are typically explored: optimization of the native producer or transferring the enzymatic pathway into a heterologous host. Recent genome sequencing of ten Penicillium species showed the vast amount of secondary metabolite gene clusters present in their genomes, and makes them accessible for rational strain improvement. In this study, we aimed to characterize the potential of these ten Penicillium species as native producing cell factories by testing their growth performance and secondary metabolite production in submerged cultivations.ResultsCultivation of the fungal species in controlled submerged bioreactors showed that the ten wild type Penicillium species had promising, highly reproducible growth characteristics in two different media. Analysis of the secondary metabolite production using liquid chromatography coupled with high resolution mass spectrometry proved that the species produced a broad range of secondary metabolites, at different stages of the fermentations. Metabolite profiling for identification of the known compounds resulted in identification of 34 metabolites; which included several with bioactive properties such as antibacterial, antifungal and anti-cancer activities. Additionally, several novel species–metabolite relationships were found.ConclusionsThis study demonstrates that the fermentation characteristics and the highly reproducible performance in bioreactors of ten recently genome sequenced Penicillium species should be considered as very encouraging for the application of native hosts for production via submerged fermentation. The results are particularly promising for the potential development of the ten analysed Penicillium species for production of novel bioactive compounds via submerged fermentations.
Highlights
Penicillium species are important producers of bioactive secondary metabolites
Organisms The species used in this study were P. coprophilum (IBT31321), P. nalgiovense (IBT 13039), P. polonicum (IBT 4502), P. antarcticum (IBT31811), P. vulpinum (IBT 29486), P. arizonense (IBT 12289), P. solitum (IBT 29525), P. decumbens (IBT11843), P. flavigenum (IBT 14082), and P. steckii (IBT 24891)
Physiology Ten different recently genome sequenced wild type Penicillium species were cultivated in 1 L controlled bioreactors to evaluate their behaviour in submerged cultivations
Summary
Penicillium species are important producers of bioactive secondary metabolites. Filamentous fungi are important producers of secondary metabolites: low-molecular-weight compounds that often have bioactive properties. Grijseels et al Fungal Biol Biotechnol (2017) 4:8 immunosuppressant mycophenolic acid [5] and the cholesterol lowering drug compactin/mevastatin [6,7,8]. These examples illustrate the great importance of Penicillium species as production hosts and sources of bioactive compounds with medical applications. The broad metabolic diversity found within the fungal kingdom, continues to provide a rich source of novel drug leads, this coupled with advancements within process engineering and physiological characterization tools, provides a strong basis for exploiting the chemical and physiological diversity in fungi to establish novel fungal based bioprocesses which can meet the demands of modern society for novel antimicrobials and pharmaceuticals
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.